Please use this identifier to cite or link to this item:
Title: Population pharmacokinetic analysis of bisoprolol in patients with acute coronary syndrome
Authors: Momčilović S.
Milovanovic, Jasmina
Jankovic, Slobodan
Jovanović, Andriana
Otašević, Suzana
Stanojevic D.
Krstić M.
Salinger, Sonja
Radojković D.
Damjanovic M.
Zivkovic M.
Maričić B.
Ranković G.
Mihajlović, Aleksandra
Nikolic V.
Issue Date: 2019
Abstract: © 2018 Wolters Kluwer Health, Inc. All rights reserved. To date, many questions about the extent and cause of pharmacokinetic (PK) variability of even the most widely studied and prescribed β1-adrenergic receptor blockers, such as metoprolol and bisoprolol, remain unanswered. Given that there are still no published population pharmacokinetic (PopPK) analyses of bisoprolol in routinely treated patients with acute coronary syndrome (ACS), the aim of this study was to determine its PK variability in 71 Serbian patients with ACS. PopPK analysis was conducted using a nonlinear mixed-effects model (NONMEM), version 7.3.0 (Icon Development Solutions). In each patient, the same formulation of bisoprolol was administered once or twice daily at a total daily dose of 0.625-7.5 mg. We separately assessed the effects of 31 covariates on the PKs of bisoprolol, and our results indicated that only 2 covariates could have possible influence on the variability of the clearance of bisoprolol: The mean daily dose of the drug and smoking habits of patients. These findings suggest that possible autoinduction of drug metabolism by higher total daily doses and induction of cytochrome P450 isoform 3A4 (CYP3A4) by cigarette smoke in liver could be the potential causes of increased total clearance of bisoprolol in patients with ACS.
Type: article
DOI: 10.1097/FJC.0000000000000644
ISSN: 0160-2446
SCOPUS: 2-s2.0-85062614022
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)




Files in This Item:
File Description SizeFormat 
  Restricted Access
29.86 kBAdobe PDFThumbnail

Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.